150 related articles for article (PubMed ID: 2909289)
1. Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells.
Pályi I; Bence J; Szikla K; Hullán L
Cancer Chemother Pharmacol; 1989; 23(1):41-6. PubMed ID: 2909289
[TBL] [Abstract][Full Text] [Related]
2. Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells.
Pályi I; Turi G; Hullán L; Szikla K; Bak M
Cancer Chemother Pharmacol; 1994; 34(1):81-5. PubMed ID: 7909724
[TBL] [Abstract][Full Text] [Related]
3. Development and some characteristics of a P388 leukemia strain resistant to 1, 2:5, 6-dianhydrogalactitol.
Bence J; Somfai-Relle S; Gáti E
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):773-80. PubMed ID: 3770035
[TBL] [Abstract][Full Text] [Related]
4. [The effect of 3,4-disuccinyldianhydrogalactitol, N-nitrosourea and their combination on DNA synthesis in normal and mouse P388 tumor cells].
Sokolova IS; Veres Z; Jakus J; Otvos LL; Gorbacheva LB
Izv Akad Nauk SSSR Biol; 1989; (4):527-33. PubMed ID: 2794230
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory and stimulatory effects of dianhydrogalactitol, an alkylating cytostatic agent on the humoral immune response.
Gerö E; Gaál D
Oncology; 1986; 43(2):98-102. PubMed ID: 3951792
[TBL] [Abstract][Full Text] [Related]
6. Effect of phenobarbital on the toxicity and antitumor activity of dibromodulcitol and dianhydrogalactitol.
Gáti E; Somfai-Relle S
Arzneimittelforschung; 1982; 32(2):149-51. PubMed ID: 7199919
[TBL] [Abstract][Full Text] [Related]
7. Survival responses to new cytostatic hexitols of P388 mouse and K562 human leukemia cells in vitro.
Pályi I
Cancer Treat Rep; 1986 Feb; 70(2):279-84. PubMed ID: 3948192
[TBL] [Abstract][Full Text] [Related]
8. Enzymological and morphological changes in rat intestinal mucosa following treatment with alkylating sugar alcohol derivatives.
Prajda N; Kralovánszky J; Kerpel-Fronius S; Gál F; Szentirmay Z
Anticancer Res; 1985; 5(4):451-6. PubMed ID: 4037742
[TBL] [Abstract][Full Text] [Related]
9. Effects of some sugar alcohol derivatives on mutation and induction of sister chromatid exchanges.
Oláh E; Tóth K; Sugár J; Hegedüs L; Somfai-Relle S
Cancer Res; 1983 Oct; 43(10):4530-6. PubMed ID: 6349793
[TBL] [Abstract][Full Text] [Related]
10. Drug sensitivity studies on clonal cell lines isolated from heteroploid tumor cell population. II. Sensitivity of clones growing in suspension cultures.
Pályi I
Neoplasma; 1980; 27(2):129-36. PubMed ID: 7393352
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of dianhydrogalactitol DAG in patients: a comparison with the human disposition of dibromodulcitol DBD.
Horváth IP; Csetényi J; Kerpel-Fronius S; Hegedüs L; Kanyár B; Eckhardt S
Eur J Cancer Clin Oncol; 1986 Feb; 22(2):163-71. PubMed ID: 3699079
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance studies on intraspecific hybridomas.
Pályi I; Turi G; Szikla K; Dallmann L
Arch Geschwulstforsch; 1981; 51(1):119-24. PubMed ID: 7259434
[TBL] [Abstract][Full Text] [Related]
13. [Effect of 1,2:5,6-dianhydrogalactitol and 1,2:5,6-dianhydro-3,4-diacetylgalactitol on DNA synthesis in the cells of melanoma B16, bone marrow, small intestine epithelium, spleen and liver of mice].
Sokolova IS; Elekes I; Otvös L; Gorbacheva LB
Biull Eksp Biol Med; 1984 Sep; 98(9):301-3. PubMed ID: 6487788
[TBL] [Abstract][Full Text] [Related]
14. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.
Institóris E; Szikla K; Otvös L; Gál F
Cancer Chemother Pharmacol; 1989; 24(5):311-3. PubMed ID: 2758560
[TBL] [Abstract][Full Text] [Related]
15. Perturbed cell kinetics of 9L rat brain tumor cells following dianhydrogalactitol.
Nomura K; Hoshino T; Deen DF; Knebel KD
Cancer Treat Rep; 1978 Dec; 62(12):2055-61. PubMed ID: 751715
[TBL] [Abstract][Full Text] [Related]
16. Benzamide potentiation of the cytotoxicity of bifunctional galactitol [correction of galacticol] in resistant P388 leukemia correlates with inhibition of DNA ligase II.
Institoris E; Fox BW; Pályi I
Cancer Chemother Pharmacol; 1992; 30(4):325-9. PubMed ID: 1643702
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.
Levin VA; Wheeler KT
Cancer Chemother Pharmacol; 1982; 8(1):125-31. PubMed ID: 7094198
[TBL] [Abstract][Full Text] [Related]
18. Effect of a single high dose and repeated small doses of dianhydrogalactitol (DAG; NSC-132313) on rat intestinal mucosa.
Kralovánszky J; Prajda N; Kerpel-Fronius S; Gál F; Szentirmay Z
Cancer Chemother Pharmacol; 1983; 11(3):167-71. PubMed ID: 6416695
[TBL] [Abstract][Full Text] [Related]
19. The interaction of dianhydrogalactitol with DNA in cultured Yoshida sarcoma cells.
Institoris E; Fox BW
Chem Biol Interact; 1978 Jul; 22(1):99-107. PubMed ID: 567539
[TBL] [Abstract][Full Text] [Related]
20. Mutagenicity of dibromodulcitol (DBD), an alkylating anticancer drug) and its mono- and bifunctional conversion products studied by the Salmonella/microsome assay.
Tóth K; Sugár J; Somfai-Relle S; Hedegüs L
Carcinogenesis; 1982; 3(3):333-6. PubMed ID: 7044598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
